Click here if you are having trouble viewing this message.

 
 
IAVI E-Newsletter: Fall Edition 
IAVI Annual Progress Report – Shorter, Visual and Online
Each year, our Annual Progress Report chronicles the contributions made by IAVI together with its partners to AIDS vaccine research and development. We are proud to present the 2012 Report, a snapshot of our achievements in a new, concise format and on an interactive website; a PDF is also available for download on the IAVI website.
 
The credit for these achievements goes to our hardworking staff and partners, and to our funders for the sustained support without which our work would not be possible. If we continue working together as we have, we will continue to make strides toward the development of a vaccine that one day will help end the AIDS pandemic.

Please click here for further details on our 2012 accomplishments, IAVI by the Numbers and news about our partnerships.
Scientific Progress, Advocacy and Tribute: IAVI & Partners at AIDS Vaccine 2013
The largest annual conference dedicated exclusively to AIDS vaccines, AIDS Vaccine 2013, held in Barcelona from 7-10 October, was a forum for 1,000 leading researchers to share and discuss the latest progress and trends. Together with its partners, IAVI presented data from clinical trials, research programs and impact modeling in more than 40 sessions – including a plenary panel, three satellite symposia and 30 oral abstract & poster presentations – and celebrated community partners in a photo exhibit and reception. Reflecting on the conference’s scientific program, IAVI Chief Scientific Officer Wayne Koff concluded: “We leave Barcelona highly energized to continue this marathon and bring a safe and effective AIDS vaccine to the people who need it most.” The 2014 conference will expand and encompass the broader biomedical HIV prevention research landscape.  The HIV Research for Prevention 2014 Conference will be held in Cape Town in October.
 
UN General Assembly Opens 68th Session
IAVI participated in many discussions about HIV / AIDS, vaccine research, global health and youth issues during the annual opening of the United Nations General Assembly. IAVI co-hosted, with UNAIDS, the International Council of AIDS Service OrganizationsInternational Civil Society Support, the International HIV/AIDS Alliance and the Global Youth Coalition on AIDS a youth panel to address the challenges of living with and being affected by HIV / AIDS within the broader context of a post-2015 development framework. IAVI and partners continue to advocate for an international commitment to ensure sufficient funding for the development of new prevention and treatment tools for HIV / AIDS, tuberculosis and malaria to help to end these diseases.
 
IAVI and IPM Co-Host Global Partners Meeting
On 19-20 September, IAVI and the International Partnership for Microbicides (IPM) hosted a first-ever joint Global Partners Meetings in Amsterdam. The meeting featured speakers from around the world, and helped highlight activities and opportunities to develop priorities and messages for the coming year collaboratively. The 35+ attendees came from 12 countries in Europe, Africa and North America and represented organizations like the World AIDS Campaign, the Global Health Technologies Coalition and the International Council of AIDS Service Organizations. Key discussion topics included the effects of treatment roll-out on the pandemic, recent developments in vaccine science and the post-2015 development agenda.
 
IAVI and GYCA Engaging Youth in Promoting New Prevention Tools
In partnership with IAVI, the Global Youth Coalition on AIDS (GYCA), a member of the ICASA YouthFront, conducted a training workshop on how to engage youth in new prevention technologies (NPTs) for HIV/AIDS, on 28-29 September in Addis Ababa. This workshop connected to the ongoing International Conference on Population and Development (ICPD) Africa Regional Review Dialogue, and convened young leaders from across the GYCA network as well as representatives from IAVI and the ICASA Youth Front Steering Committee. Presentations highlighted progress in NPT research and development, the challenges and efficacy of existing technologies and advocacy opportunities for promoting HIV prevention. Participants developed advocacy messages and campaign ideas to increase awareness, understanding and action. Further related discussions and activities will be part of the upcoming ICASA Youth Pre- and Main Conference.
 
Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV May be Feasible, Study Finds
New clinical trial findings in Uganda highlight the feasibility of intermittent treatment with pre-exposure prophylaxis (PrEP) for HIV prevention in HIV serodiscordant couples, where only one partner is HIV-positive. Encouraging safety and adherence data from a Phase I/II study show that taking PrEP less than once per day may be a potential alternative to daily treatment, which poses a long-term challenge as ensuring daily adherence among healthy people may be difficult. PLOS ONE, the scientific journal of the Public Library of Science, published findings from the study – which was conducted by researchers at the Medical Research Council (MRC) / Uganda Virus Institute (UVRI) Uganda Research Unit on AIDS in Entebbe, Uganda, and was sponsored by IAVI. The antiretroviral drug used in the study, Truvada – a combination of tenofovir and emtricitabine – was provided by the manufacturer, Gilead Sciences.
 
Valneva and IAVI Sign a New Clinical Development License Agreement for Preventive HIV Vaccine Clinical Trials
Valneva SE, a European biotechnology company focused on vaccines and antibodies research and development, has signed an EB66® cell line clinical development license agreement with IAVI for the evaluation and development of a preventive HIV vaccine candidate in clinical trials. The license allows IAVI to use Valneva’s EB66 cell line through Phase II studies of a vector-based vaccine candidate derived from a modified version of the canine distemper virus. EB66 is a proprietary cell-based technology for producing human and veterinary vaccines. The agreement is a landmark in Valneva’s history, as it is the first time the company has given dual rights to a non-profit organization to perform both research and clinical studies using its technology. IAVI looks forward to working with Valneva on this candidate as part of its broad pipeline of novel HIV vaccine candidates.
 
IAVI Shares Recent NIAID Comments in Three Major Publications
IAVI welcomes the reaffirmation of the “paramount” importance of a vaccine to ending the AIDS pandemic, and the realistic appraisal of the challenges to achieving this imperative, as outlined by Anthony S. Fauci and his colleagues at the National Institute of Allergy and Infectious Diseases (NIAID) in recent commentaries in Nature Immunology, Cell and in The Lancet. “As Dr. Fauci has repeatedly stressed, the essential quest for an AIDS vaccine is a marathon, not a sprint, and it requires sustained time, talent and resources,” said IAVI President and Chief Executive Officer Margaret McGlynn.
 
IAVI Excited about Progress that Detailed Picture of HIV Envelope Protein can Bring to Fight Against AIDS
IAVI congratulates the researchers from The Scripps Research Institute (TSRI) and Cornell University for their landmark findings published in Science, describing the structure of the HIV trimer, the outer part of the tripartite HIV envelope protein.

We are proud to have supported this research together with the National Institute of Health (NIH), among others. “These findings have collectively achieved a major, decade-long goal of AIDS vaccine research and are likely to advance and accelerate the design of vaccines to elicit broadly neutralizing antibodies against HIV,” said IAVI Chief Scientific Officer Wayne Koff.

IAVI is also enthusiastic about landmark research published in Nature by Dan Barouch et al. of the Beth Israel Deaconess Medical Center, as well as scientists at TSRI.
 
IAVI in the News
“Bring Back the Lost Girls”: IAVI's Gwynn Stevens joins Salim S. Abdool Karim of the Medical Research Council in South Africa and Sheila Tlou of UNAIDS to urge South Africa to encourage young girls to remain in school and informed about HIV prevention, Mail & Guardian (South Africa), 11 October 2013

“How Close are We to an Effective HIV Vaccine?”: IAVI CEO Margie McGlynn notes that an effective HIV vaccine with a significant level of efficacy could reduce HIV incidence by at least half, TheBodyPro.com, 10 October 2013

“Surprise Success, Disappointments, Change All Part of Ongoing Quest at Last-of-its-Kind HIV Vaccine-Focused Conference”: “Mother Nature tells us that a vaccine is possible,” says IAVI's Jill Gilmour, citing the initial suppression of the virus that most infected patients’ immune systems accomplish on their own, and pointing to existing populations, ScienceSpeaksBlog.org, 7 October 2013

“Bound for Glory”: The journal Science reviews progress in broadly neutralizing antibody research, which has transformed the search for an AIDS vaccine, recognizing the important contributions of IAVI’s Neutralizing Antibody Consortium, Science, 13 September 2013
 
 
For more of IAVI in the news, click here.


IAVI'S EFFICIENCY 


Eight-five percent of IAVI's revenue is dedicated to program costs. IAVI consistently demonstrates efficient management of resources, earning Charity Navigator three-star rating for good financial management, effectiveness, and transparency.




Copyright © 2013 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative,
IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc.

International AIDS Vaccine Initiative
NEW YORK   |   AMSTERDAM   |   JOHANNESBURG   |   LA JOLLA   |   LONDON   |   NAIROBI   |   NEW DELHI
Click here if you don't wish to receive these messages in the future.
Click . if you don't wish to receive these messages in the future.